NCT03855891 (CT-CA-miRNA) is a NA clinical trial of blood test in Ischemic Heart Disease, sponsored by I.M. Sechenov First Moscow State Medical University.

Who is sponsoring NCT03855891?

NCT03855891 is sponsored by I.M. Sechenov First Moscow State Medical University.

What drugs are being tested in NCT03855891?

Interventions in NCT03855891: blood test.

What condition does NCT03855891 study?

NCT03855891 studies Ischemic Heart Disease, Atherosclerosis.

Is NCT03855891 still recruiting?

NCT03855891 is currently completed. Last updated 22 December 2020.

Last reviewed 2020-12-22 · How we verify

NCT03855891: CT-CA-miRNA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Micro-RNA Profile in Patients With Different Stages of Atherosclerosis According to CTA

Completed NA Last updated 22 December 2020

What this trial tests

NA trial testing blood test in Ischemic Heart Disease in 81 participants. Completed in 1 October 2020.

Timeline

1 January 2019

Primary endpoint
14 August 2020

1 October 2020

Quick facts

Lead sponsor	I.M. Sechenov First Moscow State Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	81
Start date	1 January 2019
Primary completion	14 August 2020
Estimated completion	1 October 2020
Sites	1 location across Russia

Drugs / interventions tested

blood test — full drug profile →

Conditions studied

Ischemic Heart Disease — all drugs for Ischemic Heart Disease →
Atherosclerosis — all drugs for Atherosclerosis →

Sponsor

I.M. Sechenov First Moscow State Medical University

Who can join

Adults 18 to 80, any sex, with Ischemic Heart Disease or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this single-center study is to determine the spectrum and levels of cardiospecific circulating microRNAs in patients with different stages of atherosclerosis according to 640-slice multispiral computed tomography (MSCT).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs.
Skuratovskaia D, Vulf M, Komar A, Kirienkova E, et al · · 2019 · cited 42× · PMID 31212708 · DOI 10.3390/biom9060226
Network Medicine: A Clinical Approach for Precision Medicine and Personalized Therapy in Coronary Heart Disease.
Infante T, Del Viscovo L, De Rimini ML, Padula S, et al · · 2020 · cited 30× · PMID 31723086 · DOI 10.5551/jat.52407
Extracellular Non-Coding RNAs in Cardiovascular Diseases.
Jiapaer Z, Li C, Yang X, Sun L, et al · · 2023 · cited 14× · PMID 36678784 · DOI 10.3390/pharmaceutics15010155
Integrative Perspectives on Atherosclerosis: From Molecular Mechanisms to Therapeutic Approaches.
Alrahimi JS, Ahmed FA, Haneef AA, Atar D. · · 2025 · PMID 41163826 · DOI 10.4103/sjmms.sjmms_18_25

Verify or expand the search:

Other trials of blood test

Trials testing the same drug.

NCT06971289 — Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways · not yet recruiting
NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
NCT06375889 — Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage · completed
NCT05901207 — Diagnostic and Prognostic Biomarkers for IgG4-related Disease. · unknown
NCT06212505 — EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE · completed

Other recruiting trials for Ischemic Heart Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT06712862 — A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR · recruiting
NCT07009418 — Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patien · NA · recruiting
NCT06891456 — Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia · NA · recruiting

Other I.M. Sechenov First Moscow State Medical University trials

Trials by the same sponsor.

NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03855891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
Last refreshed: 22 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03855891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing